| Literature DB >> 24582788 |
Robert Adam1, Miriam Priglinger2, Timothy Harrington3, David Gottlieb4, Martin Krause5.
Abstract
Essential thrombocythemia (ET) is a risk factor for ischemic stroke and, far more rarely, hemorrhage. We report the case of an untreated 32-year-old woman with a history of JAK2 V617F-positive ET with cerebellar and subarachnoid hemorrhages without evidence of sinus vein thrombosis. She was commenced on oral cytotoxic and antiplatelet therapy. This case report discusses the underlying mechanism of hemorrhagic thrombocythemia and the management dilemma presented by the recommended treatment implications. CrownEntities:
Keywords: Hemorrhagic stroke; acquired von Willebrand disease; antiplatelet; essential thrombocythaemia; myeloproliferative disorder; young stroke
Mesh:
Substances:
Year: 2014 PMID: 24582788 DOI: 10.1016/j.jstrokecerebrovasdis.2013.12.013
Source DB: PubMed Journal: J Stroke Cerebrovasc Dis ISSN: 1052-3057 Impact factor: 2.136